Trump cracks down on H-1B that feeds Silicon Valley

April 4, 2017

Washington, Apr 4: The U.S. administration began to deliver on President Donald Trump's campaign promise to crack down on a work visa program that channels thousands of skilled overseas workers to companies across the technology industry.

trump3Fed up with a program it says favors foreign workers at the expense of Americans, the Trump administration rolled out a trio of policy shifts. The U.S. Citizenship and Immigration Services agency on Friday made it harder for companies to bring overseas tech workers to the U.S. using the H-1B work visa. On Monday, the agency issued a memo laying out new measures to combat what it called "fraud and abuse" in the program. The Justice Department also warned employers applying for the visas not to discriminate against U.S. workers.

Trump campaigned on a promise to overhaul the immigration system, calling for companies to hire more Americans instead of outsourcing jobs to countries with cheaper labor or bringing in lower-paid foreign workers. Silicon Valley's biggest tech companies, many of which were founded or run by immigrants, depend on H-1Bs and say efforts to thwart immigration threaten innovation, recruitment and startup formation. Trump's executive orders restricting travel from a handful of Muslim-majority nations led to unprecedented opposition from the industry.

But there's also broad recognition that reform is needed, given several high-profile examples where American employees have been replaced by lower-paid foreign workers through the program. Advocates for immigrants' rights also argue H-1B workers are easily exploited because their legal status is tied to a particular employer. The Economic Policy Institute estimated there were about 460,000 people working on H-1B visas in 2013.

This week's moves weren't the administration's first attempts to adjust the program. Last month, the immigration department suspended a system that expedited visa processing for certain skilled workers who paid extra. But people who have been pushing for reform had become frustrated in recent weeks that the Trump administration wasn't moving fast enough.

Outsourcing firms are considered the worst abusers of the system, an impression that the tech industry has been happy to encourage. Monday's USCIS announcement targets those firms, with the agency saying it will focus inspections on workplaces with the largest percentage of H-1B workers, and those with employees who do IT work for other companies. Shares of Cognizant Technology Solutions Corp., Infosys Ltd., Wipro Ltd. and Accenture Plc each slipped more than 1 percent on Monday.

Microsoft Corp., Facebook Inc., Alphabet Inc., Cognizant, Wipro and Accenture didn't respond to requests to comment. Infosys declined to comment, while Tata Consulting Services Ltd. said it has reduced use of high-skilled H-1B visas, while creating more U.S. IT services jobs.

The new guidelines released Friday require additional information for computer programmers applying for H-1B visas to prove the jobs are complicated and require more advanced knowledge and experience. It's effective immediately, so it will change how companies apply for the visas in an annual lottery process that begins Monday. The changes don't explicitly prohibit applications for a specific type of job. Instead, they bring more scrutiny to those for computer programmers doing the simplest jobs.

"This is a step in the right direction in terms of tightening up the eligibility," said Ron Hira, an associate professor at Howard University, who has done extensive research on the H-1B program. "You're going to have to beef up your argument for why you need this person."

Technology and outsourcing companies are the heaviest users of the H-1B visa, which is the largest program for temporary foreign workers in the U.S. by a wide margin. India-based outsourcing companies receive a disproportionate percentage of the visas and tend to pay lower salaries than U.S.-based tech firms. Employers sought H-1B visas for more than 13,000 computer programmers in 2016, citing an average salary of about $72,000, according to Bloomberg Intelligence analyst Caitlin Webber. About half of the visas sought last year were for computer-related positions, she said.

Computer programmers made up about 12 percent of all H-1B applications certified by the Department of Labor in 2015. Of those, 41 percent were for positions at the lowest wage level, defined as jobs requiring people to perform routine tasks that require them to exercise little judgment on their own. The guidelines issued Friday refer specifically to entry-level computer programmers, which the U.S. Department of Labor defines as those who write and test code to allow computer applications and software to work properly.

"This is not a change in policy on H-1B and H-1B1 eligibility in computer-related fields," CeCe Gwathmey, a spokeswoman for the immigration agency, said in an email, referencing the March 31 document. The memorandum rescinded a 17-year-old set of guidelines that "relied on obsolete information and had not been used as a standard" to decide on H-1B petitions for many years, she said.

Still, the administration hasn't thrown its lot in with any of the plans for broader changes to the program. Lawmakers from both parties have introduced several bills this year. One would replace the current random lottery with a system that gives priority to companies paying higher salaries. Another would explicitly prohibit companies from replacing qualified U.S. workers with H-1B workers.

Scott Corley, executive director Compete America, a coalition of employers that rely on high-skilled immigrants, said in a statement Monday that H-1B reform should be part of a broader re-assessment of the country's immigration priorities. "Our nation's outdated legal immigration system relies heavily on a single temporary visa category, the H-1B, to prove work authorization for every kind of high-skilled foreign professional we recruit," he said.

The result, said Corley: "Chaos, inefficiencies, and criticism."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 14,2020

Washington, Jul 14: The United States has the biggest Covid-19 testing programme in the world, better than big countries like Russia, China, India and Brazil, President Donald Trump said on Monday, asserting that America has "just about the lowest mortality rate" due to the disease in the world.

"We have one of the lowest mortality rates anywhere," Trump said at a White House roundtable. More than 34 lakh Americans have tested positive for Covid-19 so far and over 1,37,000 have died due to the disease, both of which are the largest numbers among all the countries.

The huge number of positive cases, the president said, is due to the massive testing efforts undertaken by his administration, more extensive than any other country.

"We test more than anybody by far. And when you test, you create cases. So we have created cases. I can tell you that some countries, they test when somebody walks into a hospital sick or walks into maybe a doctor's office, but usually a hospital. That is the testing they do, so they do not have cases, whereas we have all these cases. So, it is a double-edged sword," he said.

At the same time, the United States has the lowest mortality rate or just about the lowest mortality rate due to the disease in the world, Trump added. "We are doing a great job. We are doing very well with vaccines and we are doing very, very well with therapeutics. I think we are going to have some very good information coming out soon," he said in response to a question.

"But we have the best and certainly, by far, the biggest testing programme anywhere in the world. If you tested China or Russia or any of the larger countries, if you just tested India, as an example, the way we test, you would see numbers that would be very surprising. Brazil too. You know, Brazil is going through a big problem, but they do not do testing like we do," Trump said.

"So we do the testing and by doing the testing, we have tremendous numbers of cases. As an example, we have done 45 million tests. If we did half that number, you would have half the cases probably -- around that number. If we did another half of that, you would have half the numbers. Everyone would be saying, 'Oh, we are doing so well on cases'," he added.

Responding to a question, Trump said what China did to the world should not be forgotten.

"I think what China has done to the world with what took place -- the China plague -- you can call it the China virus, you can call it whatever you want to call it. It has about 20 different names. What they did to the world should not be forgotten," he said.

The trade deal with China that was signed early this year remains intact, the president said. "It is intact, they (China) are buying. Whether they buy or not, that is up to them. They are buying," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

Washington D.C, Jun 4: A lawsuit has been filed against US President Donald Trump for signing an executive order on preventing online censorship that seems to violate the freedom of speech of individuals on social media platforms.

On Tuesday, the Center for Democracy and Technology filed the lawsuit against Trump's "Executive Order on Preventing Online Censorship," which was signed May 28, 2020. The suit argues that the Executive Order violates the First Amendment by curtailing and chilling the constitutionally protected speech of online platforms and individuals.

"CDT filed suit today because the President's actions are a direct attack on the freedom of speech protected by the First Amendment. The government cannot and should not force online intermediaries into moderating speech according to the President's whims. Blocking this order is crucial for protecting freedom of speech and continuing important work to ensure the integrity of the 2020 election," said CDT President and CEO Alexandra Givens.

The executive order is designed to deter social media services from fighting misinformation, voter suppression, and the stoking of violence on their platforms, the digital rights group said.

"Access to accurate information about the voting process and the security of our elections infrastructure is the lifeblood of our democracy. The President has made clear that his goal is to use threats of retaliation and future regulation to intimidate intermediaries into changing how they moderate content, essentially ensuring that the dangers of voter suppression and disinformation will grow unchecked in an election year," Givens said.

The law firm of Mayer Brown is representing CDT in this action.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.